Indinavir (sulfate)

CAT: 0804-HY-B0689A-01Size: 50 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0689A-01Size:50 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Indinavir sulfate (MK-639) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate is also a SARS-CoV 3CLpro inhibitor[1][2][3][4].
CAS Number
[157810-81-6]
Product Name Alternative
MK-639; L735524
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; HIV; HIV Protease; MMP; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection; Cancer
Assay Protocol
https://www.medchemexpress.com/indinavir-sulfate.html
Purity
99.97
Solubility
DMSO : ≥ 100 mg/mL|H2O : 50 mg/mL (ultrasonic)
Smiles
O=C([C@@H](C[C@H](O)CN(CCN(CC1=CN=CC=C1)C2)[C@@H]2C(NC(C)(C)C)=O)CC3=CC=CC=C3)N[C@H]4C(C=CC=C5)=C5C[C@H]4O.O=S(O)(O)=O
Molecular Formula
C36H49N5O8S
Molecular Weight
711.87
Precautions
H302, H315, H319, H335
References & Citations
[1]Chavan S, et al. The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood. 2001 Jul 15;98 (2) :383-9.|[2]Esposito V, et al. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma. Clin Cancer Res. 2006 Apr 15;12 (8) :2634-9. |[3]Liu F, et al. Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol. 2005 Dec 9;354 (4) :789-800.|[4]Hall DC Jr, et al. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020 May-Jun;35:101646.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
HIV-1; MMP-2
Citation 01
BioRxiv. 2020 Apr.|Front Pharmacol. 2021 Apr 12;12:634097.|Int J Antimicrob Agents. 2019 Dec;54 (6) :814-819.|Signal Transduct Target Ther. 2021 May 29;6 (1) :212.|Antimicrob Agents Chemother. 2020 Aug 20;64 (9) :e00872-20.|Antiviral Res. 2022 Dec:208:105463.|Nat Commun. 2020 Sep 4;11 (1) :4417.|Toxicol In Vitro. 2023 Dec:93:105689.

Related Products

CatalogName
HY-B0689-01Indinavir
HY-B0689C(threo) -Indinavir
HY-B0689SIndinavir-d6
HY-B0689S1Indinavir-13C4,15N
HY-116282J-01Dextran sulfate, low sulfate (MW 5000)
HY-116282M-01Dextran sulfate, low sulfate (MW 40000)
HY-116282P-01Dextran sulfate, high sulfate (MW 5000)
HY-B1660Guanadrel (sulfate)
HY-127128Flestolol (sulfate)
HY-153993Pyrocatechol sulfate

Alternative Products

CatalogName
MBS3610533-01Indinavir sulfate
A11871-5Indinavir sulfate 5mg
A11871-25Indinavir sulfate 25mg
A11871-50Indinavir sulfate 50mg
A11871-100Indinavir sulfate 100mg
A11871-10Indinavir sulfate 10mg
RM-I140501-01Indinavir Sulfate EP Impurity A
RM-I140503-01Indinavir Sulfate EP Impurity C
I0797-50-01Indinavir Sulfate (MK-639, Crixivan)
RM-I140502-01Indinavir Sulfate EP Impurity B

Popular Products